Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
Sponsor: Windward Bio
Summary
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
105
Start Date
2026-06-02
Completion Date
2028-01-07
Last Updated
2026-06-22
Healthy Volunteers
No
Interventions
WIN378
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Placebo
Placebo matching WIN378
Locations (4)
WB Contracted Clinical Research Site
Miami Lakes, Florida, United States
WB Contracted Clinical Research Site
North Dartmouth, Massachusetts, United States
WB Contracted Clinical Research Site
Charlotte, North Carolina, United States
WB Contracted Clinical Research Site
McKinney, Texas, United States